Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methylpiperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpiperazine SCHEMBL1658174 | 1.00 | — | — | |
| Methylpiperazine SCHEMBL11679699 | 1.00 | PHGDH (0.40) | — | |
| Methylpiperazine SCHEMBL313474 | 1.00 | — | — | |
| Methylpiperazine SCHEMBL8793414 | 0.97 | PHGDH (0.39) | — | |
| Methylpiperazine SCHEMBL5375084 | 0.97 | — | — | |
| Methylpiperazine SCHEMBL54849 | 0.96 | — | — | |
| Methylpiperazine SCHEMBL12678259 | 0.96 | — | — | |
| SCHEMBL154155 | 0.96 | PHGDH (0.41) | — | |
| Methylpiperazine SCHEMBL12678256 | 0.96 | — | — | |
| Methylpiperazine SCHEMBL1363 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1399637-A | Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine and its prep. | BIOCHEMICAL PHARMACEUTICAL FAC (CN) | 2003-02-26 | — | — | CN | claimed |
| CN-1094492-C | Process for preparing 'Xidinafei' medicine | SHENYING MEDICAL CHEMICALS CO (CN) | 2002-11-20 | — | — | CN | claimed |
| CN-1283624-A | Process for preparing 'Xidinafei' medicine | SHENYING MEDICINAL CHEMICALS C (CN) | 2001-02-14 | — | — | CN | claimed |
| CN-117866015-A | Compound used in clinical management and application thereof | 联合生物科技公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112513057-B | Acylaminophosphonates and acylbenzylamines as Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for use in the treatment of cancer | 联合生物科技公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117186094-A | Synthesis method of key intermediate of valnemulin | 无锡紫杉药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4114523-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Givaudan SA (CH) | 2023-01-11 | — | — | EP | disclosed |
| CN-108513574-B | N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| EP-0177287-B1 | PYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND COMPOSITION OF THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-12-05 | — | — | EP | disclosed |
| EP-0352123-A2 | 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use | UBE INDUSTRIES LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
| US-4727073-A | CEREBOVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0177287-A2 | Pyrimidine derivatives, processes for preparation thereof and composition of the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-09 | — | — | EP | disclosed |
| US-4087550-A | Hydroxylated amine thioethers for improving the greasy and unaesthetic appearance of the hair and skin | L'OREAL (FR) | 1978-05-02 | — | — | US | disclosed |
| US-4061682-A | QUATERNARY AMMONIUM OR PHOSPHONIUM SALT | THE DOW CHEMICAL COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4009184-A | Amino carbonyl derivatives of benzofurans, processes for their production, and pharmaceutical compositions containing the same 2-phenyl-3-[3-dialkylaminopropanoyl]benzofuran compounds | KALI-CHEMIE AKTIENGESELLSCHAFT (DT) | 1977-02-22 | — | — | US | disclosed |
| US-4001293-A | Process for production of γ-halonitriles | THE DOW CHEMICAL COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3974199-A | Process for production of cyclopropylcyanide | THE DOW CHEMICAL COMPANY (US) | 1976-08-10 | — | — | US | disclosed |